Skip to main content
Equibles
IVVD logo

IVVD · Invivyd, Inc. · Metrics

Track IVVD — free

Use IVVD with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research IVVD.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.64 +0.03 (+4.36%) At close · Oct 20
Russell 2000 member Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Based on current operating plans and excluding future external financing, the Company will not have sufficient cash and cash equivalents to fund its operating expenses and capital requirements beyond one year from the issuance of these condensed consolidated financial statements, and therefore, the Company has concluded that there is substantial doubt about its ability to continue as a going concern.”
View the 10-Q filed Aug 13, 2026
Market Cap
$187.64M
Shares
294.76M
Volume · Oct 20 2.27M Avg daily vol (3M) 5M

IVVD metrics

72 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.64
Market cap
$187.64M

Price action

20 metrics
Price change (1W)
-1.5%
Price change (30D)
-37.6%
Price change (3M)
-6.7%
Price change (6M)
-60.0%
Price change (YTD)
-74.2%
Price change (1Y)
-67.7%
Trailing year
Price change (5Y)
-98.2%
52-week high
$2.88
52-week low
$0.54
Change from 52-week high
-77.9%
Change from 52-week low
+19.0%
Annualized volatility
111.4%
Annualized volatility (3M)
119.3%
Beta
2.1
RSI (14D)
39.2
Price vs SMA 50
-22.0%
Price vs SMA 200
-48.6%
Avg volume (3M)
5.00M
Relative volume
0.5
Average dollar volume
$4.04M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
294.76M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
0.5×
reciprocal yield 211.7%
EV / EBITDA
—
EV / EBIT
—
P / sales
3.2×
reciprocal yield 31.1%
P / book
1.0
reciprocal yield 96.5%
FCF yield
-58.4%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-57.2%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-09-29

Profitability

9 metrics
Gross margin
—
Operating margin
-192.8%
Trailing 12 months
Net margin
-183.9%
Gross profit (TTM)
—
Operating profit (TTM)
−$112.53M
Net income (TTM)
−$107.33M
Trailing 12 months
Diluted EPS (TTM)
$-0.31
FCF margin
-187.9%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.86

Growth

11 metrics
Revenue growth YoY
+21.2%
Year over year
Net income growth YoY
—
Revenue (TTM)
$58.37M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+167.0%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-59.3%
Return on assets
-49.0%
Debt / equity
0.0
Current ratio
5.9
EBITDA (TTM)
—
Free cash flow (TTM)
−$109.66M
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$160.08M
Latest balance sheet
Cash & equivalents
$160.08M
Total assets
$218.88M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$108.42M
Capital expenditures (TTM)
$1.24M
R&D (TTM)
$78.19M
SG&A (TTM)
$88.17M
Stock compensation (TTM)
$11.23M
R&D / revenue
134.0%
Stock compensation / revenue
19.2%

Ownership (13F)

9 metrics
13F filers
126
13F filer change QoQ
-14
Institutional ownership
79.2%
Conviction holders (share of 13F filers)
0.8%
Crowding (high-turnover and private-fund holders)
37.0%
Private-fund adviser ownership
34.2%
Active holders' share change QoQ
-4.3%
Holder tenure
6.5
Price vs estimated holder cost
-53.0%

Ownership (registered funds)

1 metrics
Index-fund ownership
8.0%

Short interest

3 metrics
Short interest
11.5%
Latest settlement · 3.6 days to cover
Days to cover
3.6d
Short-squeeze score
58 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$177,089
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1832038 CUSIP 00534A102 13F (30d) 10 filings 10 filers Visit website Investor relations